The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomas

Our group previously demonstrated that sarcoma cell lines were insensitive to epidermal growth factor receptor (EGFR) inhibitor gefitinib monotherapy. PENAO, an anti-tumour metabolic compound created in our laboratory, is currently in clinical trials. Considering the positive regulation of tumour en...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Wang, Xiaochun, Yeo, Reichelle X., Hogg, Philip J., Goldstein, David, Crowe, Philip, Dilda, Pierre J., Yang, Jia-Lin
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2020
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6967775/
https://ncbi.nlm.nih.gov/pubmed/32002123
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27416
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky